News | August 06, 2014

CardioMEMS Heart Failure Monitoring System Receives CMS New Technology Add-on Payment

August 6, 2014 — St. Jude Medical announced the Center for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment (NTAP) for the CardioMEMS heart failure (HF) monitoring system. The CardioMEMS HF system is the first and only U.S. Food and Drug Administration (FDA)-approved monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure. The NTAP program, which recognizes new technologies that provide substantial clinical improvement over already available therapies, is designed to support timely access to innovative technologies for Medicare beneficiaries.

“We are pleased CMS recognizes the substantial clinical benefit provided by the CardioMEMS HF system,” said Eric S. Fain, M.D., group president of St. Jude Medical. “This favorable decision helps ensure that Medicare patients have access to this innovative technology as we introduce CardioMEMS as a new treatment paradigm to proactively manage heart failure, improve patient outcomes and reduce hospital admissions.”

Beginning Oct. 1, 2014, CMS will reimburse hospitals an incremental amount in addition to the Medicare Severity Diagnosis Related Group (MS-DRG) payment.

More than 5 million Americans suffer from HF, which leads to 1 million hospitalizations and 2.8 million office and emergency department visits a year, and is a significant economic burden for hospitals and society. Approximately $31 billion is spent annually on HF in the United States and this cost is projected to more than double to $70 billion by 2030.

The CardioMEMS HF system allows clinicians to monitor pulmonary artery (PA) pressures in order to proactively manage medications and other treatment options while also providing an early indication of worsening HF. It is supported by strong clinical evidence, including data from the CHAMPION (“CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients”) trial published in The Lancet. The CHAMPION trial demonstrated a 37 percent reduction in HF hospitalizations during an average follow-up duration of 15 months.

For more information: www.sjm.com, www.cms.gov

Related Content

Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Diagnostics| January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
ERT Acquires iCardiac Technologies
News | Cardiac Diagnostics| December 19, 2017
ERT recently announced it has acquired iCardiac Technologies, a provider of centralized cardiac safety and respiratory...
New Study Suggests Protein Could Protect Against Coronary Artery Disease

Patients with no obstructed blood flow in the coronary arteries had higher levels of CXCL5 (blue) compared to patients with moderate levels (green) or lower levels (yellow) of CXCL5, who had increased severity of coronary obstructions (indicated by the arrows). Credit: Schisler lab

News | Cardiac Diagnostics| December 07, 2017
December 7, 2017 — The buildup of plaque in the heart’s arteries is an unfortunate part of aging.
E-cigarettes Most Likely to be Used by Alcohol Drinkers and Former Cigarette Smokers, at American Heart Association (AHA), #AHA2017.
News | Cardiac Diagnostics| December 06, 2017
December 6, 2017 — Electronic cigarettes are more frequently used by people who recently quit smoking and alcohol dri
Lack of sleep may cause heart disease in older women. American heart Association, #AHA2017
News | Cardiac Diagnostics| December 06, 2017
December 6, 2017 — Older women who do not get enough sleep were more likely to have poor cardiovascular health, accor
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
EPIC Norfolk prospective population study showed any physical activity is better than none in older adults in preventing cardiovascular disease.

The EPIC Norfolk prospective population study showed any physical activity is better than none in older adults in preventing cardiovascular disease.

News | Cardiac Diagnostics| November 24, 2017
November 24, 2017 — Any physical activity in the elderly is better than none at all for reducing cardiovascular risk,
Analytics 4 Life Presents Clinical Data on Machine-Learned Cardiac Imaging Technology at TCT 2017
News | Cardiac Diagnostics| November 01, 2017
Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary Artery Disease...
American Heart Association, Verily and AstraZeneca Launch One Brave Idea Science Innovation Center
News | Cardiac Diagnostics| October 20, 2017
The American Heart Association, Verily and AstraZeneca announced the opening of the One Brave Idea Science Innovation...
The Role of Telomere Length in Cardiovascular Risk Assessment
Feature | Cardiac Diagnostics| October 19, 2017 | Nanette H. Bishopric, M.D., FACC, FAHA
A new area of DNA testing involving telomere length may enhance a patient’s cardiovascular disease risk stratificatio
Overlay Init